- Home
- LRE vs BIVI Comparison
LRE vs BIVI Comparison
Compare LRE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BIVI
- Stock Information
- Founded
- LRE 2001
- BIVI 2013
- Country
- LRE Japan
- BIVI United States
- Employees
- LRE N/A
- BIVI N/A
- Industry
- LRE
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- BIVI Health Care
- Exchange
- LRE Nasdaq
- BIVI Nasdaq
- Market Cap
- LRE 17.6M
- BIVI 18.6M
- IPO Year
- LRE 2023
- BIVI N/A
- Fundamental
- Price
- LRE $2.00
- BIVI $1.08
- Analyst Decision
- LRE
- BIVI Strong Buy
- Analyst Count
- LRE 0
- BIVI 1
- Target Price
- LRE N/A
- BIVI $30.00
- AVG Volume (30 Days)
- LRE 20.0K
- BIVI 282.1K
- Earning Date
- LRE 07-30-2015
- BIVI 05-12-2025
- Dividend Yield
- LRE N/A
- BIVI N/A
- EPS Growth
- LRE N/A
- BIVI N/A
- EPS
- LRE 0.29
- BIVI N/A
- Revenue
- LRE $117,804,154.00
- BIVI N/A
- Revenue This Year
- LRE N/A
- BIVI N/A
- Revenue Next Year
- LRE N/A
- BIVI N/A
- P/E Ratio
- LRE $6.62
- BIVI N/A
- Revenue Growth
- LRE 8.82
- BIVI N/A
- 52 Week Low
- LRE $1.10
- BIVI $0.62
- 52 Week High
- LRE $13.76
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- LRE 84.20
- BIVI 53.42
- Support Level
- LRE $1.86
- BIVI $1.07
- Resistance Level
- LRE $1.99
- BIVI $1.13
- Average True Range (ATR)
- LRE 0.12
- BIVI 0.06
- MACD
- LRE 0.06
- BIVI 0.00
- Stochastic Oscillator
- LRE 100.00
- BIVI 65.99
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.